Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 5/20 | 0.36 |
| ▸ | F12 | P00748 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 3/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952800 | 0.83 | RBP4 (0.42) | ESR2NR1H2RBP4EP300CREBBP | |
| SCHEMBL2966970 | 0.79 | MAPK1 (0.49) | ESR2NR1H2CREBBPC5AR1 | |
| SCHEMBL17870541 | 0.76 | RBP4 (0.39) | ESR2NR1H2RBP4EP300CREBBP | |
| SCHEMBL5952667 | 0.76 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL5951628 | 0.76 | RBP4 (0.39) | ESR2NR1H2RBP4F12EP300 | |
| SCHEMBL17870535 | 0.75 | RBP4 (0.39) | ESR2NR1H2RBP4EP300CREBBP | |
| SCHEMBL5070031 | 0.75 | F12 (0.41) | ESR2NR1H2F12C5AR1MEN1 | |
| SCHEMBL25430237 | 0.75 | ADORA1 (0.43) | ESR2NR1H2RBP4F12EP300 | |
| SCHEMBL4792110 | 0.74 | ADORA1 (0.46) | ESR2NR1H2RBP4EP300CREBBP | |
| SCHEMBL14520683 | 0.74 | ESR2 (0.41) | ESR2NR1H2RBP4EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | ESR2 4683/4885NR1H2 4697/4885RBP4 4853/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | ESR2 4729/4885NR1H2 4740/4885RBP4 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.